Clinical Research
An IDE application is the gateway to the clinical evidence required for PMA approval and, increasingly, for complex 510(k)s requiring clinical data. Getting the IDE right — SR/NSR determination, protocol design, IRB strategy — determines whether your clinical program generates evidence FDA will accept.
Discuss Your IDE StrategyIDE Fundamentals
An Investigational Device Exemption (IDE), governed by 21 CFR Part 812, is required when a sponsor intends to conduct a clinical investigation involving a significant risk (SR) device that is not yet cleared or approved for the intended use under study. An IDE allows the sponsor to lawfully evaluate the investigational device in human subjects by exempting it from certain device requirements (adulteration, misbranding, 510(k), PMA, and registration requirements) during the study.
The critical upstream determination is whether the device constitutes a significant risk (SR) or non-significant risk (NSR) device. SR devices require an FDA-approved IDE before clinical investigation can begin. NSR devices are exempt from full IDE requirements — only abbreviated requirements and IRB approval are needed. The SR/NSR determination is made by the sponsor and IRB, but FDA's guidance on the factors to consider is specific: a device presents significant risk if it presents a potential serious risk to health, safety, or welfare of subjects, or if it is implanted, purports to diagnose a life-threatening condition, or is substantially important in diagnosing, curing, mitigating, or treating disease.
Mischaracterizing an SR device as NSR is a serious compliance violation with significant consequences. We review the risk determination with sponsors before any clinical activity begins and document the SR/NSR justification in a form that will withstand FDA and IRB scrutiny.
An IDE application for an SR device requires a complete, compliant submission package under 21 CFR 812.20. FDA's review focuses on whether the proposed investigation is scientifically sound, whether risks to subjects are minimized, whether informed consent procedures are appropriate, and whether the sponsor has the organizational capability to conduct the study responsibly. The application must include the investigational plan (protocol), the investigator's brochure, manufacturing information, prior investigations data, and a complete risk analysis.
The investigational plan — the clinical protocol — is the centerpiece of the application. It must be detailed enough for FDA to assess whether the study design will generate the data needed to support a future marketing application. Vague endpoints, underpowered sample size calculations, or study designs that don't align with FDA's guidance documents for the device type will generate deficiency letters. We design protocols in alignment with applicable FDA guidance, CDRH reviewer expectations, and the specific data requirements of the downstream marketing pathway (typically PMA).
FDA's Early Feasibility Study (EFS) program, available under 21 CFR 812.36, allows limited clinical investigations (typically 10 or fewer subjects) before a full pivotal trial to generate preliminary safety data and refine the device design. The EFS pathway is particularly valuable for implantable devices and Class III devices where early human data can inform pivotal trial design before large-scale clinical investment is made.
EFS applications are reviewed under an expedited process — FDA targets a 30-day review — but they require robust safety data, a rigorous risk analysis, and a well-justified rationale for human investigation before completing animal studies. We work with sponsors to structure EFS applications that satisfy FDA's requirements while preserving the development flexibility that makes EFS strategically valuable.
An IDE is required when a sponsor intends to conduct a clinical investigation involving a significant risk (SR) device that is not yet cleared or approved for the intended use under study. NSR devices are exempt from full IDE requirements and need only IRB approval under abbreviated requirements.
FDA has 30 days to review an IDE application. If FDA does not respond within 30 days, the IDE is automatically approved and the investigation may proceed. However, FDA routinely issues substantive reviews within this window — a deficiency letter extends the timeline.
A Significant Risk (SR) device presents a potential serious risk to health, safety, or welfare, or is implanted, used to diagnose a life-threatening condition, or substantially important in treating disease. SR devices need FDA-approved IDEs. Non-Significant Risk (NSR) devices need only IRB approval under abbreviated IDE requirements. Misclassifying an SR device as NSR is a serious compliance violation.
Get Started
The difference between a successful IDE and a failed one often comes down to protocol design decisions made before a single subject is enrolled. Let's get it right from the start.